Refining the Tissue Source for Biomarker-based Approaches in Renal Cell Carcinoma
- 26 September 2024
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 87 (1) , 84-85
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Sample Site Impacts RNA Biomarkers for Renal Cell CarcinomaEuropean Urology, 2024
- Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaJournal of Clinical Investigation, 2024
- Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.Journal of Clinical Oncology, 2024
- Initial screening efforts for the OPTIC RCC trial.Journal of Clinical Oncology, 2024
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeCancer Cell, 2020
- Predicting Response to Immunotherapy in Metastatic Renal Cell CarcinomaCancers, 2020
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012